ZNTL: Zentalis Pharmaceuticals, Inc.

Stock

About

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

Website
www.zentalis.com
Year Founded
2014
Employees
168
Sector
Health Care
HQ Location
San Diego, CA

Current Value

$3.01

1 Year Return

-$7.79
-72.13%

Key Details

Market Cap

$213.08M

P/E Ratio

-1.18

1Y Stock Return

-71.11%

1Y Revenue Growth

0.00%

Dividend Yield

0.00%

Price to Book

0.6

Strategies that include
ZNTL

Medium risk

$13,000

Health Care Sector

growth
balanced
growth income

This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.

Top Sector

Health Care

Top Holdings

Return

+8.40%

Expense Ratio

0.00%

Holdings

331

Create your own
strategy with

ZNTL
Three dimensional double logo

Stock's related to
ZNTL

Correlated Stocks

NameCorrelationMarket CapReturn % (1 Year)Div Yield %
ALLO41.11%$444.50M-24.82%0.00%
VIR39.27%$954.40M-26.51%0.00%
PGEN37.73%$228.91M-28.00%0.00%
CRBU37.15%$180.20M-62.45%0.00%
OSUR36.94%$287.93M-46.24%0.00%
NGNE35.38%$223.88M+32.95%0.00%
ARCT35.21%$489.20M-21.27%0.00%
FATE34.72%$248.29M-11.02%0.00%
AVO34.60%$930.35M+49.60%0.00%
PSTX34.60%$269.98M+6.13%0.00%
ALEC34.44%$377.04M-19.46%0.00%
PRTA34.39%$756.01M-56.52%0.00%
ALKS34.31%$4.45B+15.66%0.00%
EDIT34.28%$204.72M-75.49%0.00%
DENN32.88%$321.32M-35.73%0.00%
GSAT32.54%$3.29B+19.18%0.00%
IRMD31.96%$649.51M+23.95%1.18%
GPRO31.91%$179.52M-67.23%0.00%
RLGT31.87%$334.04M+15.02%0.00%
GBIO31.86%$92.84M+20.87%0.00%

Uncorrelated Stocks

NameCorrelationMarket CapReturn % (1 Year)Div Yield %
AVAV<0.01%$5.50B+51.29%0.00%
TPST0.04%$37.75M-77.59%0.00%
MNR0.09%$1.66B-10.71%15.90%
LUMO-0.14%$37.45M+41.97%0.00%
PENG-0.16%$911.79M+4.97%0.00%
RNR-0.24%$13.74B+23.09%0.58%
ARM-0.24%$139.85B+126.83%0.00%
PULM0.27%$19.83M+202.98%0.00%
JBL0.37%$14.39B-2.61%0.25%
BVN0.38%$3.16B+37.49%0.00%
NVO0.38%$342.62B-0.15%1.40%
CPSH-0.39%$20.70M-40.13%0.00%
LPLA0.39%$23.55B+38.13%0.38%
VIRT0.44%$3.17B+110.38%2.60%
CYD-0.47%$364.46M-2.94%4.26%
RILY0.48%$145.72M-79.86%20.75%
RSG0.52%$66.05B+31.79%1.04%
MPAA0.52%$134.99M-29.46%0.00%
CAE-0.53%$7.16B+7.26%0.00%
OSCR0.53%$4.45B+121.80%0.00%

ETF's related to
ZNTL

News

Yahoo

Julie Eastland appointed Chief Executive Officer, President and Director Ingmar Bruns, M.D., appointed Chief Medical Officer Scott Myers appointed to the Board of Directors as Chairperson SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced changes to its executive

Finnhub

Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib Julie Eastland appointed Chief...

Finnhub

SAN DIEGO - Zentalis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental...

Yahoo

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that on November 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 79,500 shares of the Company’s common stock and 21,000 restricte

Disclaimer

Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.

Design your own stock index

© Double Finance, 2024

Double is a registered investment adviser with the US Securities and Exchange Commission (SEC). While such registration does not imply a certain level of skill, it does require us to follow federal regulations that protect you, the investor. By law, we must provide investment advice that is in the best interest of our client. Please refer to Double's Form CRS for important additional information.

The publicly available portions of the Platform (i.e., the sections of the Platform that are available to individuals who are not party to a Client Agreement - including double.finance) are provided for educational purposes only and are not intended to provide legal, tax, or financial planning advice. To the extent that any of the content published on publicly available portions of the Platform may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Nothing on the publicly available portions of the Platform should be construed as a solicitation or offer, or recommendation, to buy or sell any security. All charts, figures, and graphs on the publicly available websites are for illustrative purposes only. Before investing, you should consider whether any investment, investment strategy, security, other asset, or related transaction is appropriate for you based on your personal investment objectives, financial circumstances, and risk tolerance. You are also encouraged to consult your legal, tax, or investment professional regarding your specific situation. Registration does not imply a certain level of skill or training.

Investing involves risk. The value of your investment will fluctuate, and you may gain or lose money.

The contents of the Platform may contain forward-looking statements that are based on management's beliefs, assumptions, current expectations, estimates, and projections about the financial industry, the economy, or Global Predictions itself. Forward-looking statements are not guarantees of the underlying expected actions or future performance and future results may differ significantly from those anticipated by the forward-looking statements. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking statements.

¹ Data as of July 2024.

² Availability of tax loss harvesting depends on portfolio diversity.

³ As of November 8, 2024. The optional Cash Sweep program takes the cash sitting in your brokerage account and moves it to an FDIC-insured interest-earning deposit account. The current yield is 1.0%, rates subject to change at any time. The cash sweep program is made available in coordination with Apex Clearing Corporation. Please read the Important Disclosures for more information.

⁴ This analysis calculator tool is for illustrative purposes only and is not financial advice. We do not guarantee the accuracy of the results or their relevance to your particular circumstances. This calculator uses hypothetical historical data and does not take into account the effect of taxes on a taxable account. Hypothetical historical data is no guarantee of future performance and this calculator is not intended to predict actual performance. The input of different time periods, amounts, and fees will vary calculator results. Average ETF fee is based on the AUM weighted average of US ETFs as of September 2024, see more information. Note that you can purchase ETFs through Double, which may incur additional fees.

Full pricing details along with an FAQ can be found here

Data displayed in charts and graphics above are for illustrative purposes only and do not reflect actual investment results and are not a guarantee of future results.

By using double.finance, you accept our and . Double is only available to US residents.

See Double Finance Form ADV Part IIA for additional information. Double does not guarantee that the results of its advice, recommendations, or the objectives of its direct index or cash management strategies will be achieved. We make no assurance that the investment process will consistently lead to successful investing. Before you invest, you should carefully review and consider your investment objectives as well as the risks, charges, and expenses of the underlying securities. There is at least a $1,000 account minimum required to participate in Double's strategies, although some strategies may have higher minimums.

Double does not provide tax, or legal advice. Double's website, brokerage, and advisory services are not intended for persons of any jurisdiction where Double is not authorized to do business. Tax savings will vary from client to client due to many factors including market conditions, tax characteristics of securities, client-imposed investment restrictions, client tax rate or status, and changes in tax regulations.